MannKind Corp (MNKD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MannKind Corp (MNKD) has a cash flow conversion efficiency ratio of 0.095x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.64 Million) by net assets ($-59.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MannKind Corp balance sheet quality to measure how much of total assets are equity-financed.
MannKind Corp - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how MannKind Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MannKind Corp (MNKD) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
MannKind Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MannKind Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jinzi Ham Co Ltd
SHE:002515
|
-0.006x |
|
Shandong Hi-Speed Road&Bridge
SHE:000498
|
0.008x |
|
Sansteel MinGuang Co Ltd Fujian
SHE:002110
|
0.114x |
|
Sixt SE
XETRA:SIX3
|
0.081x |
|
Collective Mining Ltd
TO:CNL
|
-0.091x |
|
Godrej Agrovet Limited
NSE:GODREJAGRO
|
0.153x |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
0.020x |
|
Gelex Group JSC
VN:GEX
|
-0.084x |
Annual Cash Flow Conversion Efficiency for MannKind Corp (2002–2025)
The table below shows the annual cash flow conversion efficiency of MannKind Corp from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see MannKind Corp market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-51.02 Million | $18.25 Million | -0.358x | +33.67% |
| 2024-12-31 | $-78.82 Million | $42.51 Million | -0.539x | -289.44% |
| 2023-12-31 | $-246.17 Million | $34.09 Million | -0.138x | -143.00% |
| 2022-12-31 | $-250.54 Million | $-80.70 Million | 0.322x | +9.27% |
| 2021-12-31 | $-209.35 Million | $-61.71 Million | 0.295x | +89.07% |
| 2020-12-31 | $-180.42 Million | $-28.13 Million | 0.156x | -66.43% |
| 2019-12-31 | $-190.53 Million | $-88.48 Million | 0.464x | +115.50% |
| 2018-12-31 | $-175.08 Million | $-37.73 Million | 0.216x | -28.56% |
| 2017-12-31 | $-214.73 Million | $-64.78 Million | 0.302x | -29.08% |
| 2016-12-31 | $-183.59 Million | $-78.09 Million | 0.425x | +160.37% |
| 2015-12-31 | $-350.33 Million | $-57.23 Million | 0.163x | +394.94% |
| 2014-12-31 | $-73.77 Million | $4.09 Million | -0.055x | -101.32% |
| 2013-12-31 | $-30.71 Million | $-128.73 Million | 4.191x | +287.04% |
| 2012-12-31 | $-110.68 Million | $-119.86 Million | 1.083x | +174.29% |
| 2011-12-31 | $-313.65 Million | $-123.84 Million | 0.395x | -50.72% |
| 2010-12-31 | $-185.53 Million | $-148.65 Million | 0.801x | -74.22% |
| 2009-12-31 | $-59.22 Million | $-184.08 Million | 3.108x | +199.38% |
| 2008-12-31 | $86.73 Million | $-271.29 Million | -3.128x | -364.55% |
| 2007-12-31 | $364.10 Million | $-245.15 Million | -0.673x | -36.04% |
| 2006-12-31 | $383.49 Million | $-189.79 Million | -0.495x | -1.19% |
| 2005-12-31 | $206.98 Million | $-101.23 Million | -0.489x | -22.75% |
| 2004-12-31 | $150.36 Million | $-59.91 Million | -0.398x | +15.75% |
| 2003-12-31 | $111.58 Million | $-52.77 Million | -0.473x | +11.78% |
| 2002-12-31 | $90.77 Million | $-48.67 Million | -0.536x | -- |
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve… Read more